CXCL9 and neoplasm: Although relatively few participants were enrolled in this study, the expression of PD-L1 on lung tumor cells at diagnosis was not significantly different between responders and nonresponders, and our results at least suggest that the CXCL9 level in BALF predicts ICI treatment efficacy independently of PD-L1 expression in tumor cells.